« Previous Next » Leukemia Research
Volume 29, Issue 2 , Pages 235-236 , February 2005

Thalidomide therapy for low-risk Myelodysplasia

David Bowen
- Department of Haematology, Ninewells Hospital, Dundee, Scotland, UK
- Corresponding author. Present address: Division of Pathology and Neurosciences, Ninewells Hospital, Dundee DD21HY, Scotland, UK. Tel.: +44 1382 660111; fax: +44 1382 645731.
Louisa MacIlwaine
- Department of Haematology, Ninewells Hospital, Dundee, Scotland, UK
Jamie Cavanagh
- Department of Haematology, St. Bartholomew’s and Royal London Medical School, London, England, UK
Sally Killick
- Department of Haematology, Royal Bournemouth Hospital, Bournemouth, England, UK
Dominic Culligan
- Department of Haematology, Aberdeen Royal Hospitals, Aberdeen, Scotland, UK
Ewan Thomson
- DDS Medicines Research, Ninewells Hospital, Dundee, Scotland, UK
Ghulam Mufti
- Department of Haematological Medicine, Kings College Hospital, London, England, UK

Received 29 April 2004 ,Accepted 6 May 2004.

References

Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardise response criteria for myelodysplastic syndromes. Blood 2000;96(11):3671–4.
Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98(4):958–965
- MEDLINE
- CrossRef
Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia. 2002;16(1):1–6
- MEDLINE
- CrossRef
Strupp C, Hildebrandt B, Germing U, Haas R, Gattermann N. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia. 2003;17(6):1200–1202
- MEDLINE
- CrossRef